Synthesis and antiprogestational properties of novel 17-fluorinated steroids

Steroids

Volumn 78, Issue 9, 2013, Pages 909-919

  Nickisch, Klaus ^a   Nair, Hareesh B ^c   Kesavaram, Narkunan ^a   Das, Baishakhi ^a   Garfield, Robert ^b   Shi, Shao Qing ^b   Bhaskaran, Shylesh S ^c   Grimm, Sandra L ^d   Edwards, Dean P ^d  

^a EVESTRA INC   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^c SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiprogestin; Breast cancer; Fluorine

Indexed keywords

ANTIGESTAGEN; ANTINEOPLASTIC AGENT; EC 301; EC 304; EC 305; EC 308; EC 315; FLUORINATED STEROID; MIFEPRISTONE; ORG 33628; TELAPRISTONE ACETATE; ULIPRISTAL; UNCLASSIFIED DRUG; ZK 230 211;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CARCINOGENICITY; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN CELL; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; TRANSACTIVATION;

RATTUS;

EID: 84885015460     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2013.04.003     Document Type: Article

References (37)

1. Lieberman BA, Bona BJ, Edwards DP, Nordeen SK. The constitution of a progesterone response element. Mol Endocrinol 1993;7:515-27.
2. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP. The role of extranuclear signaling actions of progesterone receptor in mediating progestrone regulation of gene expression and the cell cycle. Mol Endocrinol 2007;21:359-75.
3. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 2006;24:1115-22.
4. Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB. Expression profiing of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia 2003;8:257-68.
5. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, et al. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 2009;150:3318-26.
6. Yudt MR, Russo LA, Berrodin TJ, et al. Discovery of a novel mechanism of steroid receptor antagonism: WAY-255349 modulates progesterone receptor cellular localization and promoter interactions. Biochem Pharmacol 2011;82:1709-19.
7. Subtil-Rodriguez A, Millan-Arino L, Quiles I, Ballare C, Beato M, Jordan A. Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking. Mol Cell Biol 2008;28:3830-49.
8. Magklara A, Smith CL. A composite intronic element directs dynamic binding of the progesterone receptor and GATA-2. Mol Endocrinol 2009;23:61-73.
9. Moore MR, Zhou JL, Blankenship KA, Strobl JS, Edwards DP, Gentry RN. A sequence in the 50 flanking region confers progestin responsiveness on the human c-myc gene. J Steroid Biochem Mol Biol 1997;62:243-52.
10. Kobayashi S, Stice JP, Kazmin D, Wittmann BM, Kimbrel EA, Edwards DP, et al. Mechanisms of progesterone recpetor inhibition of inflammatory responses in cellular models of breast cancer. Mol Endocrinol 2010;24:2292-302.
11. Berrodin TJ, Jelinsky SA, Graciani N, Butera JA, Zhang Z, Nagpal S, et al. Novel progesterone receptor modulators with gene selective and context-dependent partial agonism. Biochem Pharmacol 2009;77:204-51.
12. Robertso JFR, Willscher PC, Witterbotton L, Blamly RW. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer 1999;35:214-8.
13. Klijn JGM, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000;65:825-30.
14. Klij G, De Jomg F, Bakker G. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 1989;49:2851-6.
15. Wardell SE, Edwards DP. Mechanisms controlling agonist and antagonist potential of selective progesterone receptor modulators (SPRMs). Semin Reprod Med 2005;23:9-21.
16. Poole AJ, Li Y, Kim Y, Lin S-CJ, Lee W-H, Lee P. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467.
17. Belanger A, Philibert D, Teutsch G. Regio and steriospecific synthesis of 11bsubstituted 19-norsteroids. Steroids 1981;37:361-82.
18. Garcia T, Benhamou B, Gofflo D, Vergezac A, Philibert D, Chambon P, et al. Switching agonistic, antagonistic, and mixed transcriptional responses to 11 beta-substituted progestins by mutation of the progesterone receptor. Mol Endocrinol 1992;6:2071-8.
19. Teutsch G, Philibert D. History and perspectives of antiprogestins from the chemist's point of view. Hum Reprod 1994;9(Suppl 1):12-31.
20. Schoonen WGEH, Vermeulen GJ, Deckers GH, Verbost PM, Klooserboer HJ. Antiprogestins: their mechanism of action and the consequences for compound selection by in vitro and in vivo studies. Cur Top Steroid Res 1999;2:15-54.
21. Neef G, Beier S, Elger W, Henderson D, Wiechert R. New steroids with antiprogestational and antiglucocorticoid activities. Steroids 1984;44:349-72.
22. Attardi BJ, Burgenson J, Hild SA, Reel J. In vitro antiprogestational/ antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J. Steroid Biochem. Mol. Biol. 2004;88:277-88.
23. Kloosterboer HJ, Deckers GH, Schoonen WGEJ, Hanssen RGJM, Rose UM, Verbost PM, et al. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids 2000;65:733-40.
24. Cleve A, Klar U, Schwede W. Beneficial effects of fluorine in the anti-progestin ZK 230211. J Fluorine Chem 2005;126:217-20.
25. Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000;65:713-23.
26. Nickisch K, Elger W, Cessaca J, Kesavarama N, Dasa B, Garfield R, et al. Synthesis and biological evaluation of partially fluorinated antiprogestins and mesoprogestins. Steroids 2013;78(2):255-67.
27. Guo G, Smith A. A genome-wide screen in EpiSCs identifies Nr5a nuclear receptors as potent inducers of ground state pluripotency. Development 2010;137(19):3185-92.
28. Wardell SE, Narayanan R, Weigel NL, Edwards DP. Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain co-activator and phosphorylation of serine-400. Mol Endocrinol 2010;24:335-45.
29. Beck CA, Zhang Y, Weigel NL, Edwards DP. Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem 1996;271:1209-17.
30. Ward RD, Weigel NL. Steroid receptor phosphorylation: assigning function ot site-specific phosphorylation. BioFactors 2009;35:528-36.
31. Beck CA, Zhang Y, Altmann M, Weigel NL, Edwards DP. Stoichiometry and sitespecific phosphorylation of human progesterone receptor in native target cells and in the baculovirus expression system. J Biol Chem 1996;271:19546-55.
32. Rao PN, Wang Z, Cessac JW, Rosenberg RS, Jenkins DJA, Diamandis EP. New 11b-aryl-substituted steroids exhibit both progestational and antiprogestational activity. Steroids 1998;63:523-30.
33. Liu A, Carlson E, Katzenellengogen JA. Synthesis of high affinity fluorinesubstituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. J Med Chem 1992;35:2113-29.
34. Leonhardt SA, Edwards DP. Mechanism of action of progesterone antagonists. Exp Biol Med 2002;227:969-80.
35. Press M, Spaulding B, Groshen S, Kaminsky D, Hagerty M, Sherman L, et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids 2002;67:799-813.
36. Hagan CR, Daniel AR, Dressing GE, Lange CA. Role of phosphorylation in progesterone receptor signaling and specificity. Mol Cell Endocrinol 2012;357:43-9.
37. Gass EK, Leonhardt SA, Nordeen SK, Edwards DP. The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation. Endocrinology 1998;139:1905-19.